JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1996; 28:1437-1443
© 1996 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karsch, K.
Right arrow Articles by Bonan, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karsch, K.
Right arrow Articles by Bonan, R

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation

KR Karsch, MB Preisack, R Baildon, V Eschenfelder, D Foley, EJ Garcia, M Kaltenbach, C Meisner, HK Selbmann, PW Serruys, MF Shiu, M Sujatta, and R Bonan

Department of Cardiology, Tubingen University, Germany.

OBJECTIVES: The specific objective of the REDUCE trial was to evaluate the effect of low molecular weight heparin on the incidence and occurrence of restenosis in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: Unfractionated heparin and its low molecular weight fragments possess antiproliferative effects and have been shown to reduce neointimal smooth muscle cell migration and proliferation in response to vascular injury in experimental studies. METHODS: The REDUCE trial is an international prospective, randomized, double-blind, multicenter study. Twenty-six centers in Europe and Canada enrolled 625 patients with single-lesion coronary artery obstructions suitable for PTCA. Three hundred six patients received reviparin as a 7,000-U bolus before PTCA, followed by 10,500 U as an infusion over 24 h and then twice-daily 3,500-U subcutaneous application for 28 days. The 306 patients in the control group received a bolus of 10,000 U of unfractionated heparin followed by an infusion of 24,000 U over 24 h. These patients then underwent 28 days of subcutaneous placebo injections. The primary end points were efficacy (defined as a reduction in the incidence of major adverse events [i.e., death, myocardial infarction, need for reintervention or bypass surgery]), absolute loss of minimal lumen diameter and incidence of restenosis during the observation period of 30 weeks after PTCA. RESULTS: Using the intention to treat analysis for all patients, 102 (33.3%) in the reviparin group and 98 (32%) in the control group have reached a primary clinical end point (relative risk [RR] 1.04, 95% confidence interval [CI] 0.83 to 1.31, p = 0.707). Likewise, no difference in late loss of minimal lumen diameter was evident for both groups. Acute events within 24 h occurred in 12 patients (3.9%) in the reviparin group and 25 (8.2%) in the control group (RR 0.49, 95% CI 0.26 to 0.92, p = 0.027) during or immediately after the initial procedure. In the control group, eight major bleeding complications occurred, and in the reviparin group, seven were observed within 35 days after PTCA. CONCLUSIONS: Reviparin use during and after coronary angioplasty did not reduce the occurrence of major clinical events or the incidence of angiographic restenosis over 30 weeks.


This article has been cited by other articles:


Home page
Arch Intern MedHome page
R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot
Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials
Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
L. R Moser and J. S Kalus
Role of Low-Molecular-Weight Heparin in Invasive Management of Non-ST-Elevation Acute Coronary Syndromes
Ann. Pharmacother., December 1, 2004; 38(12): 2094 - 2104.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz
Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 576S - 599S.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J R S Day, I S Malik, A Weerasinghe, M Poullis, I Nadra, D O Haskard, K M Taylor, and R C Landis
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention
Heart, July 1, 2004; 90(7): 794 - 799.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H.-P. Bestehorn, F.-J. Neumann, H. J. Buttner, P. Betz, P. Sturzenhofecker, E. von Hodenberg, A. Verdun, L. Levai, J. P. Monassier, and H. Roskamm
Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2160 - 2165.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman
Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
Heart, June 1, 2004; 90(6): e37 - e37.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Moliterno, J. B. Hermiller, D. J. Kereiakes, E. Yow, R. J. Applegate, G. A. Braden, E. J. Dippel, M. I. Furman, C. L. Grines, N. S. Kleiman, et al.
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study
J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1132 - 1139.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. C. Wong, R. P. Giugliano, and E. M. Antman
Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention
JAMA, January 15, 2003; 289(3): 331 - 342.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R.e. Choussat, G. Montalescot, J. P. Collet, E. Vicaut, A. Ankri, V. Gallois, G.e. Drobinski, I. Sotirov, and D. Thomas
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1943 - 1950.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
P. Kujath, C. Eckmann, and F. Misselwitz
Low-Molecular-Weight Heparin in Arterial Reconstructive Surgery: A Double-Blind, Randomized Dose-Finding Trial
Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 337 - 345.
[Abstract] [PDF]


Home page
HeartHome page
G Niccoli and A P Banning
Heparin dose during percutaneous coronary intervention: how low dare we go?
Heart, October 1, 2002; 88(4): 331 - 334.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas
Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris
Circulation, February 6, 2001; 103(5): 658 - 663.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
G. G Nenci and A. Minciotti
Low molecular weight heparins for arterial thrombosis
Vascular Medicine, November 1, 2000; 5(4): 251 - 258.
[Abstract] [PDF]


Home page
Eur Heart JHome page
N Meneveau, F Schiele, G Grollier, B Farah, J.M Lablanche, K Khalife, J Machecourt, N Danchin, J.E Wolf, M Simpson, et al.
Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS Trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study
Eur. Heart J., November 1, 2000; 21(21): 1767 - 1775.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Kageyama, H. Yamamoto, and R. Yoshimoto
Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs
Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2303 - 2308.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
D. S Ettenson and E. R Edelman
Local drug delivery: an emerging approach in the treatment of restenosis
Vascular Medicine, May 1, 2000; 5(2): 97 - 102.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
D. M Templeton, Y. Zhao, and M. Y. Fan
Heterogeneity in the response of vascular smooth muscle to heparin: altered signaling in heparin-resistant cells
Cardiovasc Res, January 14, 2000; 45(2): 503 - 512.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W.-m. Cheung, M. R. D’Andrea, P. Andrade-Gordon, and B. P. Damiano
Altered Vascular Injury Responses in Mice Deficient in Protease-Activated Receptor-1
Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 3014 - 3024.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Betriu, M. Masotti, A. Serra, J. Alonso, F. Fernandez-Aviles, F. Gimeno, T. Colman, J. Zueco, J. L. Delcan, E. Garcia, et al.
Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): A four-year follow-up
J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1498 - 1506.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. E. Hart, L. W. Kraiss, S. Vergel, D. Gilbertson, R. Kenagy, T. Kirkman, D. L. Crandall, S. Tickle, H. Finney, G. Yarranton, et al.
PDGFß Receptor Blockade Inhibits Intimal Hyperplasia in the Baboon
Circulation, February 2, 1999; 99(4): 564 - 569.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
A. Gershlick
Endovascular manipulation to restrict restenosis
Vascular Medicine, August 1, 1998; 3(3): 177 - 188.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
A. Lafont and D. Faxon
Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials?
Cardiovasc Res, July 1, 1998; 39(1): 50 - 59.
[Full Text] [PDF]


Home page
CirculationHome page
J.-M. Lablanche, E. P. McFadden, N. Meneveau, J. R. Lusson, B. Bertrand, J.-P. Metzger, V. Legrand, G. Grollier, C. Macaya, B. de Bruyne, et al.
Effect of Nadroparin, a Low-Molecular-Weight Heparin, on Clinical and Angiographic Restenosis After Coronary Balloon Angioplasty : The FACT Study
Circulation, November 18, 1997; 96(10): 3396 - 3402.
[Abstract] [Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1996 by the American College of Cardiology Foundation.